lisdexamfetamine dimesylate

FDA Drug Profile — Vyvanse, Lisdexamfetamine Dimesylate, LISDEXAMFETAMINE DIMESYLATE, lisdexamfetamine dimesylate

lisdexamfetamine dimesylate is listed in the FDA National Drug Code directory with 52 NDC codes, marketed under brand names including Vyvanse, Lisdexamfetamine Dimesylate, LISDEXAMFETAMINE DIMESYLATE. Available dosage forms: capsule, tablet, chewable.

Drug details

Generic Name
lisdexamfetamine dimesylate
Brand Names
Vyvanse, Lisdexamfetamine Dimesylate, LISDEXAMFETAMINE DIMESYLATE, lisdexamfetamine dimesylate
Application Number
NDA021977
Sponsor
Takeda Pharmaceuticals America, Inc.
NDC Codes
52
Dosage Forms
CAPSULE, TABLET, CHEWABLE
Routes
ORAL
Active Ingredients
LISDEXAMFETAMINE DIMESYLATE

Indications and Usage

1 INDICATIONS AND USAGE Lisdexamfetamine dimesylate capsules and lisdexamfetamine dimesylate chewable tablets are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies ( 14.1 )] Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies ( 14.2 )] . Limitations of Use: The use of lisdexamfetamine dimesylate is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5), Use in Specific Populations (8.4)]. Lisdexamfetamine dimesylate is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of lisdexamfetamine dimesylate for the treatment of obesity have not been established [see Warnings and Precautions ( 5.2 )] . Lisdexamfetamine dimesylate capsules and lisdexamfetamine dimesylate chewable tablets are a central nervous system (CNS) stimulant indicated for the treatment of ( 1 ): Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older Moderate to severe binge eating disorder (BED) in adults Limitations of Use: The use of lisdexamfetamine dimesylate is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage (5.5, 8.4) Lisdexamfetamine dimesylate is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of lisdexamfetamine dimesylate for the treatment of obesity have not been established ( 5.2 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.